NeuroSense Therapeutics has received approval from the Nasdaq Hearings Panel for a listing extension on the Nasdaq Capital Market until October 31, 2024. This decision follows the company's hearing on August 1, where it presented its compliance plan to address the June 21 notice regarding insufficient stockholders' equity.The extension provides additional time for NeuroSense to demonstrate compliance with Nasdaq's Listing Rule 5550(b), which requires a minimum stockholders' equity of $2.5 million. The company must meet all required conditions within this timeframe to maintain its listing status.

NeuroSense Therapeutics has received approval from the Nasdaq Hearings Panel for a listing extension on the Nasdaq Capital Market until October 31, 2024. This decision follows the company's hearing on August 1, where it presented its compliance plan to address the June 21 notice regarding insufficient stockholders' equity.The extension provides additional time for NeuroSense to demonstrate compliance with Nasdaq's Listing Rule 5550(b), which requires a minimum stockholders' equity of $2.5 million. The company must meet all required conditions within this timeframe to maintain its listing status.